Inhibition of Galectins in Cancer: Biological Challenges for Their Clinical Application

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jan 27

PMID 36703969

Authors

Diego Jose Laderach

Daniel Compagno

Affiliations

Soon will be listed here.

Abstract

Galectins play relevant roles in tumor development, progression and metastasis. Accordingly, galectins are certainly enticing targets for medical intervention in cancer. To date, however, clinical trials based on galectin inhibitors reported inconclusive results. This review summarizes the galectin inhibitors currently being evaluated and discusses some of the biological challenges that need to be addressed to improve these strategies for the benefit of cancer patients.

Citing Articles

Galectins and Liver Diseases.

Mimura S, Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T Int J Mol Sci. 2025; 26(2).

PMID: 39859504 PMC: 11766161. DOI: 10.3390/ijms26020790.

Vascular galectins in tumor angiogenesis and cancer immunity.

Thijssen V Semin Immunopathol. 2024; 46(1-2):3.

PMID: 38990363 PMC: 11239785. DOI: 10.1007/s00281-024-01014-9.

Tandem-repeat lectins: structural and functional insights.

Olvera-Lucio F, Riveros-Rosas H, Quintero-Martinez A, Hernandez-Santoyo A Glycobiology. 2024; 34(7).

PMID: 38857376 PMC: 11186620. DOI: 10.1093/glycob/cwae041.

Biophysical and Structural Characterization of the Interaction between Human Galectin-3 and the Lipopolysaccharide from .

Pirone L, Pia Lenza M, Di Gaetano S, Capasso D, Filocaso M, Russo R Int J Mol Sci. 2024; 25(5).

PMID: 38474141 PMC: 10932368. DOI: 10.3390/ijms25052895.

Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme.

Elliott Jr W, Tsung A, Guda M, Velpula K Am J Cancer Res. 2024; 14(2):774-795.

PMID: 38455415 PMC: 10915327.

References

Joeh E, OLeary T, Li W, Hawkins R, Hung J, Parker C . Mapping glycan-mediated galectin-3 interactions by live cell proximity labeling. Proc Natl Acad Sci U S A. 2020; 117(44):27329-27338. PMC: 7959530. DOI: 10.1073/pnas.2009206117. View

Cheong T, Shin J, Chun K . Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci. 2009; 101(1):94-102. PMC: 11159305. DOI: 10.1111/j.1349-7006.2009.01364.x. View

Liu F, Patterson R, Wang J . Intracellular functions of galectins. Biochim Biophys Acta. 2002; 1572(2-3):263-73. DOI: 10.1016/s0304-4165(02)00313-6. View

Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim H, Raz A . Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2001; 277(9):6852-7. DOI: 10.1074/jbc.M107668200. View

Stillman B, Hsu D, Pang M, Brewer C, Johnson P, Liu F . Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol. 2006; 176(2):778-89. DOI: 10.4049/jimmunol.176.2.778. View

Dimitroff C . Galectin-Binding O-Glycosylations as Regulators of Malignancy. Cancer Res. 2015; 75(16):3195-202. PMC: 4537818. DOI: 10.1158/0008-5472.CAN-15-0834. View

Demotte N, Wieers G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K . A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 2010; 70(19):7476-88. DOI: 10.1158/0008-5472.CAN-10-0761. View

Honke K, Tsuda M, Koyota S, Wada Y, ISHIZUKA I, Nakayama J . Molecular cloning and characterization of a human beta-Gal-3'-sulfotransferase that acts on both type 1 and type 2 (Gal beta 1-3/1-4GlcNAc-R) oligosaccharides. J Biol Chem. 2000; 276(1):267-74. DOI: 10.1074/jbc.M005666200. View

Griffioen A, Thijssen V . Galectins in tumor angiogenesis. Ann Transl Med. 2014; 2(9):90. PMC: 4205869. DOI: 10.3978/j.issn.2305-5839.2014.09.01. View

10.

Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M . Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemother Pharmacol. 2013; 72(4):879-87. DOI: 10.1007/s00280-013-2270-2. View

11.

Astorgues-Xerri L, Riveiro M, Tijeras-Raballand A, Serova M, Rabinovich G, Bieche I . OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur J Cancer. 2014; 50(14):2463-77. DOI: 10.1016/j.ejca.2014.06.015. View

12.

Nobumoto A, Oomizu S, Arikawa T, Katoh S, Nagahara K, Miyake M . Galectin-9 expands unique macrophages exhibiting plasmacytoid dendritic cell-like phenotypes that activate NK cells in tumor-bearing mice. Clin Immunol. 2008; 130(3):322-30. DOI: 10.1016/j.clim.2008.09.014. View

13.

Limagne E, Richard C, Thibaudin M, Fumet J, Truntzer C, Lagrange A . Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019; 8(4):e1564505. PMC: 6422400. DOI: 10.1080/2162402X.2018.1564505. View

14.

Pedrosa L, Raz A, Fabi J . The Complex Biological Effects of Pectin: Galectin-3 Targeting as Potential Human Health Improvement?. Biomolecules. 2022; 12(2). PMC: 8961642. DOI: 10.3390/biom12020289. View

15.

Michel A, Nangia-Makker P, Raz A, Cloninger M . Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation. Chembiochem. 2014; 15(14):2106-12. PMC: 4511962. DOI: 10.1002/cbic.201402134. View

16.

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q . Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2020; 268:120546. DOI: 10.1016/j.biomaterials.2020.120546. View

17.

Bieg D, Sypniewski D, Nowak E, Bednarek I . MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 2018; 299(4):1077-1087. PMC: 6435611. DOI: 10.1007/s00404-018-4999-7. View

18.

Yang Q, Hou C, Huang D, Zhuang C, Jiang W, Geng Z . miR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer. Oncol Lett. 2017; 13(3):1958-1964. PMC: 5403439. DOI: 10.3892/ol.2017.5608. View

19.

Friedrich M, Aigner A . Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs. 2022; 36(5):549-571. PMC: 9396607. DOI: 10.1007/s40259-022-00549-3. View

20.

Zhou Q, Munger M, Veenstra R, Weigel B, Hirashima M, Munn D . Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117(17):4501-10. PMC: 3099570. DOI: 10.1182/blood-2010-10-310425. View